



October 3-6, 2021

 **2021** Ryan White
HIV/AIDS Program
CLINICAL CONFERENCE

Contents

General Information.....	2
The HIV/AIDS Bureau of the Health Resources and Services Administration.....	4
International Antiviral Society–USA	4
AIDS Education and Training Center National Coordinating Resource Center	7
Conference Co-Chairs and Faculty	8
Conference Faculty and Organizer’s Financial Relationships With Ineligible Companies	10
CLINICAL CONFERENCE Overview	12
Continuing Education Credits.....	13

General Information

WELCOME AND GOALS

Welcome to the *virtual 2021 Ryan White HIV/AIDS Program (RWHAP) CLINICAL CONFERENCE*. The goals of the *virtual 2021 RWHAP CLINICAL CONFERENCE* are to:

- Provide key updates in HIV medicine for practitioners in RWHAP-funded clinics and programs
- Equip attendees with information and tools for sharing this key information with clinic staff and colleagues

OVERVIEW

The *virtual 2021 RWHAP CLINICAL CONFERENCE* is from Sunday, October 3 to Wednesday, October 6. The *virtual 2021 RWHAP CLINICAL CONFERENCE* will provide state-of-the-art updates on research, prevention, care, and treatment issues in the medical management of HIV infection for experienced HIV clinical decision makers.

The *virtual 2021 RWHAP CLINICAL CONFERENCE* is planned with and supported by the HIV/AIDS Bureau (HAB), Health Resources and Services Administration (HRSA) of the US Department of Health and Human Services (DHHS) and is sponsored for continuing medical education and organized by the International Antiviral Society-USA (IAS-USA). This conference is coordinated through the AIDS Education and Training Center National Coordinating Resource Center (AETC NCRC). The 4 days of the *virtual 2021 RWHAP CLINICAL CONFERENCE* include a mix of lectures, case-based interactive presentations, and small-group meet-the-expert breakout sessions.

ABOUT OUR ATTENDEES

- **645** participants
- **28** faculty
- **314** Physicians; **196** Nurse Practitioners; **52** Physician Assistants; **54** Registered Nurses; **28** Pharmacists

Table 1: Registrant Breakdown by Type

Physician	314	48.3%
Nurse Practitioner	196	30.3%
Physician Assistant	52	8.2%
Registered Nurse	54	8.5%
Pharmacist	29	4.5%
Total	645	100%

Figure 1: Number of Patients With HIV Under Direct Care (N=639)





Figure 2: Number of RWHAP CLINICAL CONFERENCE Attended in the Past (N=639)



CONFERENCE FUNDING

This conference is funded by Health Resources and Services Administration (HRSA) of the US Department of Health and Human Services (DHHS) under grant number U10HA28686 (AIDS Education and Training Center National Coordinating Resource Center) awarded François-Xavier Bagnoud Center from the Rutgers University School of Nursing with a sub award to International Antiviral Society–USA (IAS–USA) to sponsor this CME activity.

General Information (continued)

ACCESSING THE VIRTUAL CONFERENCE

The virtual conference is hosted on the IAS–USA website (www.IASUSA.org). You will need your IAS–USA login information to access all virtual content. To access the **virtual 2021 RWHAP CLINICAL CONFERENCE**, please visit the website at <https://www.iasusa.org/events/virtual-rwcc2021/>

This year, the live conference general sessions are hosted through Zoom Webinar. Attendees will submit questions to the presenters through the Q and A box, answer audience polls, and chat with other attendees all within the Zoom Webinar. Breakout sessions are hosted through Zoom Meetings. Out of respect to the breakout session leaders, please turn your camera on when you join. Breakout session participants will submit questions through the chat box for the session leader to answer.

ON-DEMAND SESSIONS

Recordings of the general session lectures and case-based presentations will be available within **24 to 48 hours** following the presentation for registered attendees. These on-demand sessions will be linked to the **virtual 2021 RWHAP CLINICAL CONFERENCE** home page. Full access to the virtual content will be available approximately 2 weeks following the

conclusion of the conference. Please note: meet-the-expert breakout sessions will not be recorded.

POSTCONFERENCE MATERIALS AND RESOURCES

An important goal of the **virtual 2021 RWHAP CLINICAL CONFERENCE** is to provide attendees with the resources to update their clinical colleagues who were not able to attend the conference. To that end, a Slide Training Guide with PowerPoint slides and recordings of each general session lecture and case-based presentation will be available after the **virtual 2021 RWHAP CLINICAL CONFERENCE**. About 2 months after the conference, you will be asked to summarize the postconference updates and trainings that you have conducted for your clinic staff and colleagues.

DRUG AND PRODUCT DISCLAIMER

This activity may contain information about the investigational uses of drugs or products that are not approved by the US Food and Drug Administration. Please consult full prescribing information before using any medication or product mentioned in this activity.

The views and opinions expressed are those of the faculty and do not necessarily represent the opinions or recommendations of the IAS–USA.

The HIV/AIDS Bureau of the Health Resources and Services Administration

The Health Resources and Services Administration (HRSA), an agency of the U.S. Department of Health and Human Services, is the primary federal agency for improving health care for people who are geographically isolated, economically or medically vulnerable. Tens of millions of Americans receive quality, affordable health care and other services through HRSA's 90-plus programs and more than 3,000 grantees.

The HRSA Ryan White HIV/AIDS Program (RWHAP) provides a comprehensive system of HIV primary medical care, essential support services, and medications for low-income people with HIV who are uninsured and underserved. The Program funds grants to states, cities/counties, and local community-based organizations to provide care and treatment services to people with HIV to improve health outcomes and reduce HIV transmission.

More than half of people with diagnosed HIV in the U.S. receive services through the RWHAP each year. That means more than half a million people received services through the Program.

Over the last 31 years, HRSA's RWHAP has played a critical role in the U.S. public health response to HIV. The Program serves as an important source of ongoing access to HIV medication that can enable people with HIV to live close to normal lifespans. In 2019, 88.1% of RWHAP clients were virally suppressed, which exceeds the national average of 65%.

Funded through a cooperative agreement with HRSA, the RWHAP Clinical Conference further supports the principles of the HIV/AIDS Bureau and HRSA.

International Antiviral Society—USA

MISSION

The mission of the International Antiviral Society—USA (IAS—USA) is to improve the prevention, treatment, care, and quality of life for people with or at risk of HIV or other viral infections and their associated health conditions through high-quality, relevant, balanced, and needs-oriented education and information for practitioners and scientists who are actively involved in medical care and research.

ACCREDITATION STATEMENT

The IAS—USA is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

BOARD OF DIRECTORS

Nonstaff board members serve in a volunteer capacity and are not compensated for their roles in oversight and governance of the organization. As part of its duties, the board oversees the needs assessment, design, development, and evaluation of all educational programs. Visit www.iasusa.org/about/ias-usa-board-of-directors/ for a list of Board of Directors members.

IMPROVING THE MANAGEMENT OF HIV DISEASE®: ADVANCED CME COURSES IN HIV PATHOGENESIS, ANTIRETROVIRALS, AND

OTHER SELECTED ISSUES IN HIV DISEASE MANAGEMENT (VIRTUAL IN 2021)

These one-day courses are designed for HIV specialists who are actively involved in HIV disease management or research. The virtual courses are half-day updates that focus on the key issues clinicians are likely facing. Nationally and internationally recognized faculty provide advanced-level presentations with balanced, timely, scientifically rigorous, and clinically relevant information about HIV disease management. Visit www.iasusa.org/activities/live-courses/hiv-courses/ for more information on upcoming and on-demand CME courses.

WEBINARS

The IAS–USA offers state-of-the-art webinars on the evolving challenges of managing HIV disease as part of a nationwide continuing medical education (CME) effort for physicians. They are led by nationally and internationally recognized faculty. Each webinar lasts 75 to 90 minutes and provide continuing education credits. Visit www.iasusa.org/activities/webinars/upcoming-webinars/ for upcoming webinars. On-demand webinars offer CME credit for a year at www.iasusa.org/activities/webinars/on-demand-webinars/.

Webinar topics and presenters are identified by the *Cases on the Web Board (COW)* Board, a select group of experts in the management of HIV and other viral infections. Visit www.iasusa.org/activities/cases-on-the-web/about-cows/cow-webinars-editorial-board/ for a list of COW Board members.

CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS

The IAS–USA partners with the Conference on Retroviruses and Opportunistic Infections (CROI) Foundation to sponsor CROI, the most important HIV research conference worldwide. Webcasts, electronic posters, and abstracts from CROI 2014 to 2021 are available at www.CROIconference.org.

TOPICS IN ANTIVIRAL MEDICINE™

The IAS–USA publishes the peer-reviewed journal *Topics in Antiviral Medicine™* 4 to 6 times a year as a resource for physicians and other health care practitioners who are actively involved in the care of people with HIV or other viral infections. The journal offers CME credit and is indexed on *Index Medicus/MEDLINE*. Visit <https://www.iasusa.org/activities/topics-in-antiviral-medicine/current-issues/> to view the journal.

TREATMENT AND TESTING GUIDELINES

The IAS–USA sponsors the development of clinical practice guidelines. The guidelines are written by independent volunteer panels of researchers and clinicians from around the world and focus on management issues for which definitive evidence is lacking. Guidelines for viral load testing, antiretroviral therapy, behavioral and biomedical HIV prevention, HIV drug resistance testing, cytomegalovirus infection, and metabolic complications have been published.

Recommendations on the use of antiretroviral drugs for treatment and prevention of HIV infection in adults, by the IAS–USA Antiretroviral Guidelines Panel, have been published

in the *Journal of the American Medical Association*. Visit www.iasusa.org/resources/guidelines for updates.

Recommendations on the use of antiretroviral drugs for treatment and prevention of HIV infection in adults, by the IAS–USA Antiretroviral Guidelines Panel, were published in the *Journal of the American Medical Association* on October 14, 2020 (Saag MS, Gandhi RT, Hoy JF et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society–USA panel. *JAMA*. 2020:E1-19). *JAMA* offers free access to the paper at www.jamanetwork.com/journals/jama/fullarticle/2771873. The paper includes updated recommendations for the use of antiretroviral therapy in adults with established HIV infection, including new recommendations on what regimens to start, updated approaches to prescribing preexposure prophylaxis (PrEP), new recommendations on management of aging among people with HIV, and overview of the then understanding of the intersection of COVID-19 disease and HIV.

HIV DRUG RESISTANCE MUTATIONS

Through the HIV Drug Resistance Mutations Panel, the IAS–USA provides regular updates on the mutations associated with resistance to antiretroviral drugs. A volunteer panel of acknowledged leaders in the field collect and review the information on relevant mutations. This information, last updated in July 2019, is available in *Topics in Antiviral Medicine™*, and on the IAS–USA website at www.iasusa.org/resources/hiv-drug-resistance-mutations/.

COVID-19: WHAT WE KNOW TODAY. A DIALOGUE ABOUT THE PUBLIC HEALTH, SCIENTIFIC, AND CLINICAL ASPECTS OF THE PANDEMIC

The COVID-19 pandemic has created an urgent need for reliable scientific information. The IAS–USA COVID-19 Dialogues bring together 2 or more leading experts to discuss the latest science regarding COVID-19 and what the data and research are telling us about the basic science, public health, and clinical aspects of the disease, and the consequences of the pandemic.

Visit <https://www.iasusa.org/activities/covid-19-dialogue-series/> for upcoming live Dialogues. The conversations are available on-demand as webcasts and podcasts after they are broadcast at www.iasusa.org/activities/covid-19-dialogue-series/on-demand/.

PODCASTS

Many past IAS–USA activities are available as podcasts and may be downloaded from the IAS–USA website. Visit www.iasusa.org/resources/podcasts for details and a list of available presentations.

PRACTICE QUESTION OF THE WEEK

This new initiative started in 2021 and highlights updates to relevant practice guidelines or identified practice gaps. Each question is programmed as a pop-up and on the resources page on the IAS–USA website. Participants receive immediate feedback with the correct answer, explanation, and links to

more resources. Visit <https://www.iasusa.org/practice-question-of-the-week/> to view the most recent question and to see past questions.

PRESENTATION SLIDES

The IAS–USA offers a collection of downloadable presentation slides from various activities. Slides may be downloaded as PowerPoint files from the IAS–USA website at www.iasusa.org/resources/key-slides/.

For information about any of these programs, please contact the IAS–USA.

Phone: (415) 544-9400

Email: registration@iasusa.org • Website: www.iasusa.org



AIDS Education and Training Center National Coordinating Resource Center

The AIDS Education and Training Center National Coordinating Resource Center (AETC NCRC) provides education, capacity building, and other training resources for regional AETCs along with the coordination and organization of AETC network communities of practice to support the mission to offer timely, high-quality, state-of-the-science information to health care professionals working with existing and emerging populations affected by HIV. The AETC Program is a component of the Ryan White HIV/AIDS Program

(RWHAP) consisting of a network of 8 regional AETCs, 2 national AETCs, the National HIV Curriculum (NHC) project, and 2 projects to integrate the NHC into health professional education. The AETC NCRC is supported by the Health Resources and Services Administration (HRSA) of the US Department of Health and Human Services (HHS) under grant number U1OHA28686 awarded to the François-Xavier Bagnoud Center from the Rutgers University School of Nursing.

Conference Co-Chairs and Faculty


CHAIRS



Laura W. Cheever, MD, ScM
Associate Administrator
Chief Medical Officer
HIV/AIDS Bureau
Health Resources and Services Administration
Rockville, Maryland



Allison Agwu, MD
Professor of Pediatric and Adult
Infectious Diseases
The Johns Hopkins University
Baltimore, Maryland




Michael S. Saag, MD
Professor of Medicine
Associate Dean for Global Health
Jim Straley Chair in AIDS Research
University of Alabama at Birmingham
Birmingham, Alabama


SPEAKERS, PANELISTS, AND BREAKOUT SESSION LEADERS



Wendy Armstrong, MD
Professor of Medicine
Emory University
Atlanta, Georgia



Jodie Dionne-Odom, MD
Associate Professor
University of Alabama at Birmingham
Birmingham, Alabama



Roger J. Bedimo, MD
Chief, Infectious Diseases Section
Veterans Affairs North Texas Health Care System
Professor of Medicine
University of Texas Southwestern Medical Center
Dallas, Texas




Monica Gandhi, MD, MPH
Professor of Medicine
University of California San Francisco
San Francisco, California



Connie L. Celum, MD, MPH
Professor, Department of Medicine
Adjunct Professor of Epidemiology
Harborview Medical Center
University of Washington
Seattle, Washington



Rajesh T. Gandhi, MD
Professor of Medicine
Harvard Medical School
Boston, Massachusetts



Francine Cournos, MD
Professor of Clinical Psychiatry in Epidemiology
Columbia University
New York, New York



Khalil G. Ghanem, MD, PhD
Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, Maryland



Susan Cu-Uvin, MD
Professor of Obstetrics and Gynecology, and
Medicine
Brown University
Providence, Rhode Island



Meredith Greene, MD
Associate Professor of Medicine
University of California San Francisco
San Francisco, California



Judith S. Currier, MD
Professor of Medicine
University of California Los Angeles
Los Angeles, California



Rachel Bender Ignacio, MD, MPH
Assistant Professor
University of Washington
Director, COVID-19 Clinical Research Center
Fred Hutchison Cancer Research Center
Seattle, Washington



Nadine J. Kaslow, PhD
 Professor of Psychiatry and Behavioral Sciences
 Emory University
 Atlanta, Georgia



Melanie A. Thompson, MD
 Co-chair
 HIV Medicine Association/Infectious Diseases Society
 of America HIV Primary Care Guidance Panel
 Atlanta, Georgia



Jennifer J. Kiser, PharmD, PhD
 Associate Professor
 University of Colorado Skaggs School of Pharmacy
 and Pharmaceutical Sciences
 Aurora, Colorado



Ronald D. Wilcox, MD
 Medical Officer
 HIV/AIDS Beureau
 Health Resources and Services Administration
 Rockville, Maryland



Raphael J. Landovitz, MD
 Professor of Medicine
 University of California Los Angeles
 Los Angeles, California



Timothy J. Wilkin, MD, MPH
 Associate Professor of Medicine
 Weill Cornell Medicine
 New York, New York



James Raper, PhD, DSN, CRNP, JD
 Professor of Medicine and Nursing
 University of Alabama at Birmingham
 Birmingham, Alabama

SPECIAL SNDAY PANEL MEMBERS



Marcus Conant, MD
 Co-Founder, San Francisco AIDS Foundation
 San Francisco, California



Michael Reyes, MD, MPH
 Professor of Family Community Medicine
 University of California San Francisco
 San Francisco, California



Kathleen A. Clanon, MD
 Director, Alameda Care Connect
 Oakland, California



Paul A. Volberding, MD
 Professor of Medicine
 University of California San Francisco
 San Francisco, California



Alison Moed Paolercio, RN
 Head Nurse, AIDS Ward
 San Francisco General Hospital
 San Francisco, California

Conference Faculty and Organizer's Financial Relationships With Ineligible Companies (Formerly Described as Commercial Interests by ACCME)

FACULTY FINANCIAL DISCLOSURE

It is the policy of IAS–USA to ensure balance, independence, objectivity, and scientific rigor in all its educational activities. All parties with control over the content of IAS–USA activities (eg, members of the Board of Directors, Advisory Board Members, activity chairs, authors, faculty, and IAS–USA staff) are required to disclose to the organization and activity audience any financial relationships with ineligible companies (formerly described as commercial interests by the ACCME) within the previous 24 months.

The **ACCME defines financial relationships** as “those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria for promotional speakers’ bureau, ownership interest (eg, stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected. The ACCME has not set a minimum dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.”

The **ACCME defines ineligible companies** as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.”

It is IAS–USA policy to separate ineligible company promotion from its core educational and informational activities. Individuals who conduct marketing or promotional activities for ineligible companies may not contribute to IAS–USA programs. A marketing or promotional activity includes any activity in which the ineligible company controls key elements, such as speaker or topic selection that could be used to serve the ineligible company’s interests (eg, speakers’ bureaus, lectures, and advertorials). Individuals may not

participate in most IAS–USA programs for 12 months after functioning in a promotional or marketing effort for an ineligible company. The Conference on Retroviruses and Opportunistic Infections (CROI), a research conference, does allow presenters to take part in such activities, but conflicts of interest are resolved before their CROI presentations.

IAS–USA policy requires that it resolve any real or apparent conflict of interest that may influence the development, content, or delivery of its educational activities prior to the activity being delivered to participants.

The IAS–USA has several mechanisms for resolving conflicts of interest in educational activities. If the conflict of interest cannot be resolved through these mechanisms, the party is removed from the activity.

It is the policy of IAS–USA to publish the financial interests of all parties in control of the content of its activities on activity materials or, in cases where space is limited (eg, reprints of figures), on the IAS–USA website, through a web address printed on the activity material. This information will also be provided directly by the IAS–USA office upon request.

The IAS–USA documents the date of the disclosure along with financial relationship information. As previously stated, the information published will reflect financial conflicts incurred within the previous 24 months. Individuals who refuse to disclose financial interests will not participate in the CME activity. It should be understood that other organizations may have different policies with regard to financial conflicts and with regard to the time period covered in the disclosure of financial conflicts.

In collaborative projects (eg, publication of materials in medical literature), the IAS–USA may adhere to the additional disclosure and conflict-of-interest policies of the collaborating journal.

Conference Faculty and Organizer's Financial Relationships With Ineligible Companies (Continued)

Below are the financial relationships with ineligible companies that faculty members of this conference have had within the past 24 months as of the date listed.

CONFERENCE CO-CHAIRS

Dr Cheever has no relevant financial affiliations to disclose. (Updated 009/29/21)

Dr Agwu has served as an advisor to Gilead Sciences, Inc, and Merck & Co, Inc. (Updated 09/29/21)

Dr Saag has received research grants and support awarded to his institution from Gilead Sciences, Inc, and ViiV Healthcare. (Updated 09/28/21)

SPEAKERS AND BREAKOUT SESSION LEADERS

Dr Armstrong has no relevant financial relationships with ineligible companies to disclose. (Updated 06/04/21)

Dr Bedimo has received grants and research support awarded to the Veterans Affairs North Texas Healthcare System from Merck & Co, Inc. He has served as a scientific advisor for Merck & Co, Inc, ViiV Healthcare, and Gilead Sciences, Inc. (Updated 09/27/21)

Dr Bender Ignacio has served as a consultant for AbbVie and Seagan. (Updated 09/23/21)

Dr Celum has served as a scientific advisor to Merck & Co, Inc, and Gilead Sciences Inc. (Updated 07/16/20)

Dr Cournos has no relevant financial affiliations to disclose. (Updated 9/29/21)

Dr Cu-Uvin receives royalties from UpToDate. (Updated 09/20/21)

Dr Currier has no relevant financial relationships with ineligible companies to disclose. (Updated 09/20/21)

Dr Dionne-Odom has no relevant financial relationships with ineligible companies to disclose. (Updated 08/26/21)

Dr M. Gandhi has no relevant financial affiliations to disclose. (Updated 09/07/21)

Dr R. Gandhi has no relevant financial affiliations to disclose. (Updated 09/07/21)

Dr Ghanem has no relevant financial relationships with ineligible companies to disclose. (Updated 09/20/21)

Dr Greene has received grants paid to her institution from Gilead Sciences, Inc. (Updated 03/08/21)

Dr Kaslow has no relevant financial affiliations to disclose. (Updated 02/11/21)

Dr Kiser has received funding paid to her institution for an investigator-initiated pharmacokinetic study with Gilead Sciences, Inc. (Updated 10/01/21)

Dr Landovitz has served on scientific advisory boards for Gilead Sciences, Inc, and Merck & Co, Inc. (Updated 09/20/21)

Dr Raper has no relevant financial relationships with ineligible companies to disclose. (Updated 09/20/21)

Dr Thompson's institution (ARCA, Atlanta, GA) has received grants for research from Bristol Myers Squibb, Frontier Biotechnologies, CytoDyn, Inc, Cepheid, Inc, Gilead Sciences, Inc, Merck & Co, Inc, and ViiV Healthcare. (Updated 10/28/21)

Dr Wilcox has no relevant financial relationships with ineligible companies to disclose. (Updated 09/26/21)

Dr Wilkin has served as a consultant to Merck & Co, Inc/ViiV Healthcare, and has received grant support awarded to his institution from Merck & Co, Inc/ViiV Healthcare. (Updated 10/01/21)

CLINICAL CONFERENCE Overview

The *virtual 2021 RWHAP CLINICAL CONFERENCE* will provide state-of-the-art updates on research, prevention, care, and treatment issues in the medical management of HIV infection.

Upon completion of the *virtual 2021 RWHAP CLINICAL CONFERENCE*, participants will be able to:

- Describe the new aspects to the Ryan White HIV/AIDS Program
- Identify situations in which the choice of antiretroviral regimen should consider particular clinical circumstances, such as comorbid conditions, coinfections, pregnancy, and issues in older patients
- Describe the most current data on currently available and investigational new antiretroviral drugs, formulations, and strategies
- Initiate and monitor HIV prevention intervention strategies, including the use of preexposure prophylaxis (PrEP), in individuals at risk for HIV infection
- Describe the current epidemiology, clinical presentations, and management of the most common sexually transmitted infections (STIs) in adults with HIV infection and in special populations such as adolescents
- Detect, manage, and prevent common comorbidities occurring in the aging population of persons with HIV infection, including how to manage and prevent polypharmacy
- Describe the current understanding of COVID-19 in people with HIV
- Identify ways to prevent HIV-related comorbidities in adolescents
- Detect and address depression in patients with HIV, as well as practitioner and staff burnout
- Describe the current best practices of perinatal HIV care and prevention
- Describe barriers and strategies for engaging out-of-care patients with HIV
- Describe the risk factors and screening recommendations for non-AIDS cancers in people with HIV
- Describe challenges and opportunities for utilizing telemedicine for the prevention and treatment of HIV

EDUCATIONAL FORMAT

The *virtual 2021 RWHAP CLINICAL CONFERENCE* will promote active participation by HIV practitioners throughout the 4 days of lectures, case-based panel discussions, workshops, and question-and-answer periods. Attendees are encouraged to bring cases and questions for discussion to breakout sessions.

- Lectures provide state-of-the-art updates on timely and clinically relevant issues around HIV diagnosis and management, and management of related conditions.
- Case presentations outline patient histories, and attendees use an audience response system to register their diagnostic or treatment choices. Faculty members use clinical decision points in case presentations as springboards for discussing new data and current diagnostic and therapeutic topics in HIV management and prevention. Select case presentations are enhanced with a panel of experts.
- Question-and-answer periods give the audience, faculty, and panelists extended opportunities to review complex topics in HIV management.
- Meet-the-expert breakout sessions allow clinical decision makers to have time with experts. Each workshop is 60 minutes in length. Attendees should review their workshop assignment in the final notes email they received for their individual schedule.

We encourage you to provide your comments and suggestions on the online conference evaluation and overall conference evaluation forms at <http://www.iasusa.org/events/rwcc2021/>

Please note that screen capturing, photographing, videotaping, or audio recording presentations is not permitted. On-demand sessions will be available at www.iasusa.org/resources/webcasts/

ASSESSMENT OF NEEDS

The goal of the *virtual 2021 RWHAP CLINICAL CONFERENCE* is to provide a comprehensive and timely overview of HIV treatment issues and current strategies in HIV medical care for practitioners in Ryan White HIV/AIDS Program, Parts A-, B-, C-, and D-funded clinics/programs.

INTENDED AUDIENCE

This is an advanced-level conference that is designed for physicians, nurse practitioners, physician assistants, and other key clinical decision makers in Ryan White HIV/AIDS Program-funded clinics and programs who are experienced in HIV medicine.

Continuing Education Credits

ACCREDITATION STATEMENT AND CME CREDITS

Physicians (MD, DO, and international equivalents) are eligible to receive CME credit for participation in the **virtual 2021 RWHAP CLINICAL CONFERENCE**.



The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The IAS–USA designates this live activity for a maximum of **14.5 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC POINTS FOR INTERNAL MEDICINE SPECIALISTS AND SUBSPECIALISTS



Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to **14.5 MOC points** in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

NURSING CONTINUING EDUCATION CONTACT HOURS

Educational Review Systems is an approved approver of continuing nursing education by the Alabama State Nursing Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Provider # 5-115. This program is approved for **14.5 hours** of continuing nursing education.

Educational Review Systems is also approved for nursing continuing education by the state of California, the state of Florida and the District of Columbia.

This program is approved for **14.5 hours** of pharmacotherapy credit.

PHARMACY CONTINUING EDUCATION CONTACT HOURS



Educational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Participants of the session who complete the evaluation and provide accurate NABP e-Profile information will have their credit for **14.5 contact hours** (1.45 CEU) submitted to CPE Monitor as early as 14 days after the event and no later than 60 days after the event. Please know that if accurate e-Profile information is not provided within 60 days of the event, credit cannot be claimed after that time. The participant is accountable for verifying the accurate posting of CE credit to their CPE Monitor account within 60 days.
UAN # 0761-9999-21-304-L02-P

AMERICAN ACADEMY OF FAMILY PHYSICIANS (AAFP) CREDITS

The AAFP has reviewed virtual 2021 Ryan White HIV/AIDS Program CLINICAL CONFERENCE and deemed it acceptable for up to **13.5 Online Only, Live AAFP Prescribed credit**. Term of Approval is from 10/03/2021 to 10/06/2021. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Education Credits (Continued)

CLAIMING CME CREDITS OR A CERTIFICATE OF PARTICIPATION

Obtaining CME credit, American Board of Internal Medicine’s Maintenance of Certification (ABIM MOC) points, Nursing or Pharmacy credits, American Academy of Family Physicians (AAFP) credit, or a certificate of participation will require that you complete the posttest. After the activity has ended, a link to the posttest will be activated in your IAS–USA account under **My Activities**.

How to Claim CME Credits and/or ABIM MOC Points

1. Log in to your [IAS-USA](#) account.
2. Hover over your name and click **My Activities**.
3. Find the relevant activity in the table and, in the far-right column, click on the **gray sunburst icon** (☀).
4. Complete the posttest. Click **Take the CME/ABIM MOC Posttest** to start the test. Note: Be sure to indicate if you are claiming ABIM MOC points, which will require a passing grade of 70%
5. **FINAL STEP:** After completing the posttest, at the top of the Thank you page, click **Online CME Claim Form**, where, once logged in, you will: a) answer “Yes” to the question “Are you a licensed physician?” b) enter the CME hours you wish to claim, and c) click **Submit**.

A certificate will then be available for you to print. You can also view your certificate from your IAS–USA account under My Activities. Find the relevant activity in the table and, in the far-right column, click on the green sunburst icon (☀) to print your certificate. Submit the claim form no later than 30 days after the date of the activity.

ABIM MOC points are intended for internal medicine physicians in the United States who are maintaining their ABIM certification. The points will only be awarded after the successful completion of the posttest. The ABIM will upload the points to your member account after 30 days and notify you by email when it has done so.

You must have an ABIM ID number to earn ABIM MOC points. This is a 6-digit number issued by ABIM. Be sure to include that number and your date of birth on your IAS–USA profile page.

How to Claim Pharmacy Credits

Be sure to provide your 6-digit NABP CPE number and your date of birth on your IAS–USA profile. Your claim will not be approved without them.

1. Follow steps 1 through 3 above.
2. Complete the posttest. Click **Take the CE Posttest** to start the test.
3. **FINAL STEP:** After completing the posttest, at the top of the Thank you page, click **Online CME Claim Form**, where, once logged in, you will: a) answer “No” to the question “Are you a licensed physician?” and b) click **Submit**.

A certificate will then be available for you to print. You can also view your certificate from your IAS–USA account under My Activities. Find the relevant activity in the table and, in the far-right column, click on the green sunburst icon (☀) to print your certificate. Submit the claim form no later than 30 days after the date of the activity.

We work with Educational Review Systems to deliver credit to pharmacy professionals, and your credits will be posted to your NABP CPE profile directly from that organization.

How to Claim Nursing Credits

1. Follow steps 1 through 3 above.
2. Complete the posttest. Click **Take the CE Posttest** to start the test.
3. **FINAL STEP:** After completing the posttest, at the top of the Thank you page, click **Online CME Claim Form**, where, once logged in, you will: a) answer “No” to the question “Are you a licensed physician?” and b) click **Submit**.

A certificate will then be available for you to print. You can also view your certificate from your IAS–USA account under My Activities. Find the relevant activity in the table and, in the far-right column, click on the green sunburst icon (☀) to print your certificate. Submit the claim form no later than 30 days after the date of the activity.

We work with Educational Review Systems to deliver credit to nursing professionals, and your credit notification will be emailed directly from that organization.

How to Claim AAFP Credits

1. Login to your AAFP account.
2. Search for course title, “*virtual* 2021 Ryan White HIV/AIDS Program CLINICAL CONFERENCE”
3. Claim your credits